Vascular smooth muscle cells (VSMC) in mature, normal blood vessels exhibit a differentiated, quiescent, contractile morphology, but injury induces a phenotypic modulation toward a proliferative, de-differentiated, migratory phenotype with upregulated extracellular matrix protein synthesis (synthetic phenotype) which contributes to intimal hyperplasia. The mTOR pathway inhibitor rapamycin inhibits intimal hyperplasia in animal models and in human clinical trials. We report that rapamycin treatment induces differentiation in cultured synthetic phenotype VSMC from multiple species. VSMC treated with rapamycin assumed a contractile morphology, quantitatively reflected by a 67% decrease in cell area. Total protein and collagen synthesis were also inhibited by rapamycin. Rapamycin induced expression of the VSMC differentiation marker contractile proteins SM -actin, calponin, and SM myosin heavy chain (SM-MHC), as observed by immunoblotting and immunohistochemistry. Notably, we detected a striking rapamycin induction of calponin and SM-MHC mRNA, suggesting a role for mTOR in transcriptional control of VSMC gene expression. Rapamycin also induced expression of the cyclin dependent kinase inhibitors p21 cip and p27 kip , consistent with cell cycle withdrawal.
Introduction
Intimal hyperplasia is an important clinical problem associated with most vascular interventions. This can lead to restenosis in up to 40% of coronary balloon angioplasties or arterial bypass grafts (25) . These secondary lesions are often of greater severity than the original lesion, and require repeated intervention. Intimal hyperplasia is precipitated by vessel injury, and may be the result of an uncontrolled healing response. Vascular smooth muscle cells (VSMC) in normal, mature vessels are quiescent, contractile, and differentiated, but assume a proliferative, migratory, and protein synthetic phenotype in response to injury (2) . VSMC proliferation, migration to the intima, and synthesis of extracellular matrix (ECM) after injury is an important component of intimal hyperplasia. Thus, understanding the processes which control VSMC differentiation may contribute to a better understanding of how pharmacologic interventions may limit restenosis.
VSMC do not terminally differentiate, but retain plasticity to de-differentiate toward a proliferative, synthetic phenotype in response to injury. As the primary function of mature VSMC is contraction, the complement of contractile, structural, and regulatory proteins expressed in fully differentiated VSMC provides markers of differentiation status (37) . These include smooth muscle (SM) myosin heavy chain (SM-MHC), calponin, and SM -actin. The SM-MHC SM2 isoform is considered the most stringent marker of the differentiated state (19).
Expression of these proteins decreases as VSMC de-differentiate and myofilaments break down.
Differentiation is often accompanied by expression of the cyclin/CDK inhibitors p21
cip (waf-1) and p27 kip (44) .
Many factors may contribute to VSMC de-differentiation after injury, including denudation of the endothelium, altered contacts with ECM and integrins, and exposure to growth factors. Culturing VSMC in vitro mimics this progression, as primary cultures rapidly lose differentiation markers and exhibit a synthetic phenotype (10) . Such cell culture models have provided insights into factors which influence VSMC phenotype. Exposure to growth factors including PDGF, EGF, and TGF , or unsaturated lysophosphatidic acid promotes dedifferentiation (37) , (12) , (10) , but G protein coupled receptor agonists in serum, including thrombin, can induce VSMC differentiation via G subunits (32). TGF can also promote SMC differentiation in pluripotent stem cells (35) , (14) . ECM components influence VSMC phenotype, as culture on laminin, especially in combination with insulin-like growth factor I (IGF-I) (10), (11) promotes a differentiated phenotype. Neighboring cells also provide important inputs, as bilayer co-culture of VSMC opposite endothelial cells induces VSMC differentiation (5) . Although little is known about the intermediate signaling mechanisms underlying these effects, IGF-I-mediated SMC differentiation is inhibited by wortmannin, suggesting the involvement of PI 3-Kinase (PI 3-K) (10), (11) .
Here, we investigate the effects of the macrolide antibiotic rapamycin on VSMC differentiation. Rapamycin has been previously shown to inhibit VSMC proliferation, protein synthesis, and migration in vitro, and intimal hyperplasia in animal models (3), (24) , (30) , (7), (40) , (33) , (1) and in human clinical trials (26) , (38) . Rapamycin binds FKBP12, and this complex inhibits mTOR, the mammalian target of rapamycin (also known as FRAP or RAFT) (21) . mTOR is a ubiquitously expressed protein kinase which regulates translation initiation of specific growth-related mRNA subsets through the effectors p70 S6 kinase 1 (S6K1) and 4E-BP1/eIF4E. Other mTOR-regulated effectors included S6K2, PKC , and eIF2 kinase. The mTOR signaling pathway regulates protein synthesis in response to amino acids, and these effectors integrate nutrient-sufficiency signals from mTOR with growth factor signals via PI 3-Kinase (PI3K) to coordinately regulate protein synthesis, cell cycle progression, and proliferation (21) . No studies of rapamycin in VSMC have addressed differentiation, which is characterized by major changes in gene expression and morphology. We report that the mTOR inhibitor rapamycin induces biochemical differentiation of primary VSMC in culture, and that one mTOR effector, S6K1, may play and important role in this process.
Materials and Methods

Cell Culture
Bovine thoracic aortic endothelial (EC) and bovine vascular smooth muscle cells (VSMC) were isolated and cultured in Dulbecco's Modified Eagle's Medium (DMEM) with 10% calf serum, L-glutamine, and penicillin-streptomycin. Rat and porcine VSMC were isolated from thoracic aorta and cultured as above but with 10% fetal bovine serum (36). Human VSMC were isolated from arterial or venous samples from vascular surgery patients or organ donors and cultured in M199 media with 10% fetal bovine serum, L-glutamine, penicillin-streptomycin, insulin, hEGF, and hFGF (Clonetics). Human aortic VSMC were also purchased from Clonetics.
EC were harvested by scrape technique and VSMC by explant method (5 
Adenoviral Overexpression of S6K1
We have generated recombinant adenoviruses encoding HA-tagged wild type or rapamycin-resistant mutant (ED 3 E) (41) p70 S6K1. These viruses co-express green fluorescent protein (GFP) to easily assess infection efficiency using the AdEasy system (see www.coloncancer.org/adeasy for methods) (13). Virus encoding GFP alone serves as a control. 
Immune Complex Kinase Assay
Infected VSMC were lysed (as for Western blotting) and S6K1 immunoprecipitated with an antibody to the HA-epitope tag and Protein A sepharose. Kinase activity toward recombinant GST-S6 peptide in washed immunoprecipitates was assayed as in Martin et al (23) .
Results
Rapamycin induces contractile morphology
We assessed the effects of rapamycin on VSMC differentiation using primary aortic smooth muscle cell cultures from multiple species. VSMC in primary culture rapidly dedifferentiate in early passages from their in vivo contractile phenotype to a synthetic phenotype, characterized by a flattened morphology, increased protein synthesis, and loss of contractile protein expression (10) . However, VSMC treated with 20 nmol/L rapamycin (a maximal concentration for inhibition of S6K1 and 4E-BP1) for 48 hours underwent a phenotypic modulation with morphology characteristic of the differentiated, contractile phenotype ( Figure   1A ). As has been previously reported (24) , rapamycin inhibited proliferation as determined by cell number (data not shown). We have previously demonstrated that VSMC phenotype is influenced by the presence of endothelial cells (EC) (5) . Bilayer co-culture of VSMC and EC on opposite sides of a porous membrane inhibits VSMC extracellular matrix synthesis and induces a contractile morphology (5) . The effect of rapamycin on VSMC cultured alone is similar to the effects of EC co-culture (Fig. 1B ). This dramatic change in VSMC morphology is quantitatively reflected in measurements of cell area (two dimensional). VSMC treated with rapamycin for 48 hours were 67% smaller in area than VSMC treated with ethanol vehicle (Fig. 1B ).
Rapamycin inhibits VSMC protein and extracellular matrix synthesis
Rapamycin is a known inhibitor of specific translation initiation and thus inhibits protein synthesis in many cell types (8), (20) . Enhanced synthesis of collagen and other extracellular matrix proteins is a characteristic of the synthetic, de-differentiated VSMC phenotype, and is a major component of intimal hyperplasia (5) . We labeled VSMC with 3 H-amino acids to assess total protein and collagen synthesis after rapamycin treatment. As expected, rapamycin inhibited both total protein and collagen synthesis after 24-48 hours ( Fig. 2A) . Notably, rapamycin treatment inhibited total protein synthesis by only 30% after 48 hours, while cycloheximide treatment inhibited total protein synthesis by 93% at this time point (Fig. 2B ). This is consistent with rapamycin inhibition of translation of a subset of highly structured mRNAs, whereas cycloheximide inhibits global protein synthesis.
Rapamycin induces protein markers of VSMC differentiation
Given the striking effects on VSMC morphology, we assessed modulation of VSMCspecific contractile protein gene expression, which serve as biochemical markers of differentiation status. Rapamycin treatment induced a rapid upregulation of the mRNA for basic calponin in human VSMC as determined by semi-quantitative RT-PCR (Fig. 3B ). This isoform is unique to vascular smooth muscle and is down-regulated upon de-differentiation (37) . A sharp 20-fold induction of the calponin message was observed after 2 hour rapamycin treatment. A maximal 35-fold induction was reached after 6 hour rapamycin treatment. The elevated mRNA levels persisted through 24 hours. We similarly evaluated mRNA levels for SM-myosin heavy chain (SM-MHC), the most stringent contractile protein marker of VSMC differentiation (19).
Rapamycin also induced SM-MHC mRNA levels, with a maximal 6-fold induction after 1 hour treatment ( Fig 3C) . These data suggest that rapamycin may promote a differentiated phenotype by inducing a new program of gene expression at the level of transcription, a new role for the mTOR pathway in mammalian cells.
Inhibition of mTOR with rapamycin induced expression of contractile protein markers of the differentiated phenotype, including smooth muscle (SM) -actin, calponin, and the SMmyosin heavy chain (MHC) SM2 isoform, considered to be the most stringent marker for differentiated VSMC (19). Notably, the kinetics of induction of these proteins closely followed those observed for induction of calponin message (Fig. 4A) . With all contractile proteins assayed, protein levels continued to accumulate with increasing time of rapamycin treatment.
Confirming the effects of rapamycin on contractile protein gene expression observed at early time points, 48 hour rapamycin treatment induced expression of smooth muscle (SM) -actin, calponin, and SM2-MHC in VSMC in western blot analyses (Fig 4B-C, 6D -E). We have also observed this new contractile protein expression by immunofluorescent staining (Fig. 4D , 6B-C). Enhanced expression of these proteins is consistent with the differentiated morphology observed after 48 hour rapamycin treatment in Figure 1 . Notably, induction of contractile proteins was specific to inhibition of the mTOR pathway, as treatment with pharmacological inhibitors of other signaling pathways, including the PI 3-K, p38, and ERK1/2 pathways, did not induce contractile protein expression (Fig. 4C) . Furthermore, rapamycin fold induction of contractile protein expression relative to vehicle was highly reproducible in VSMC from all species tested (Table 1) .
Rapamycin induces expression of anti-proliferative cyclin-dependent kinase inhibitors
Because proliferation and differentiation are not necessarily mutually exclusive processes in VSMC, we assessed expression levels of cyclin-dependent kinase inhibitory proteins following rapamycin treatment. Rapamycin treatment induced expression of the p27 kip and p21 cip cyclin-dependent kinase inhibitors in VSMC (Fig. 5) , consistent with rapamycin-inhibited proliferation. Notably, the kinetics of rapamycin-induced p27 kip and p21 cip expression closely parallel the kinetics of contractile protein induction, suggesting a coordinated regulation of proliferation and differentiation. Rapamycin induction of these cyclin-dependent kinase inhibitors was also highly reproducible in VSMC from all species tested (Table 1) .
The mTOR effector S6K1 opposes rapamycin-induced VSMC differentiation
Our data suggest that activation of the mTOR pathway opposes VSMC differentiation.
Rapamycin inhibits the activity of mTOR, which in turn regulates multiple downstream effector 6D ). To further enhance S6K1 activity in the presence of rapamycin, we employed an adenovirus encoding an HA-tagged rapamycin-resistant mutant of S6K1 (ED 3 E) (41). This mutant S6K1 retained 75% of its initial activity in the presence of rapamycin when expressed in rat VSMC (Fig. 6A, bottom panel) . Rapamycin similarly induced expression of SM2-MHC in control infected cells, but not in S6K1-ED 3 E-infected cells, as determined by western blotting (Fig. 6E) . The difference in SM2-MHC induction between control and S6K1-ED 3 E-infected cells was statistically significant (p=0.01). Immunoblots confirmed overexpression of S6K1
(note that mobility shift of ED 3 E in Fig. 6E is less sensitive to rapamycin than wild type S6K1 in Fig. 6D ), and ERK1/2 blots verified even lane loading (Fig. 6E) . These data indicate that overexpression of the mTOR effector S6K1 inhibits rapamycin-induced VSMC differentiation.
Discussion
We demonstrate for the first time that inhibition of the mTOR pathway induces VSMC differentiation as determined by induction of contractile protein expression and morphology.
Importantly, our data provide evidence suggesting that this involves transcriptional regulation, a largely unexplored function for the mTOR signaling pathway which is best known for translational regulation. We have also employed a unique approach allowing assignment of a role to one particular mTOR effector, p70 S6K1, in VSMC phenotypic modulation.
The mTOR inhibitor rapamycin has previously been shown to inhibit VSMC The most intriguing aspect of this work was the finding that inhibition of mTOR by rapamycin induces mRNAs encoding contractile proteins. Because calponin mRNA was undetectable in the vehicle treated de-differentiated VSMC and was rapidly induced 20-fold after 2 hour rapamycin treatment, this induction is likely due to new transcription. We are investigating the possibility that rapamycin may additionally regulate message stability. Similar induction of SM-MHC mRNA suggests that mTOR-dependent transcriptional regulation may be a common mechanism among VSMC differentiation marker proteins. Notably, the kinetics of contractile protein expression closely follow the induction of these messages.
While the TOR pathway is known to regulate nutrient-sensitive transcription factors in yeast (15) , very little is known regarding transcriptional control by mTOR in mammalian cells.
However, several studies have reported that rapamycin induces hematopoietic differentiation (11), (16), (43), but inhibits adipocyte differentiation (6) and chondrogenesis (27) . Differential effects of rapamycin on differentiation in other cell lines suggests that mTOR may indeed be an important regulator of cell type-specific transcriptional processes. We are currently evaluating mTOR-regulated VSMC-specific transcription factor candidates (manuscript in preparation).
To address potential mechanisms of rapamycin-induced biochemical differentiation, we evaluated the role of S6K1, a key mTOR target, in VSMC differentiation. S6K1 promotes cell growth and proliferation, in addition to protein synthesis via 5'TOP mRNA regulation (21) . As these processes are characteristic of de-differentiated VSMC, S6K1 activation may antagonize differentiation. However, as there are multiple effector proteins, including 4E-BP1 (8) and S6K2
(23), downstream of mTOR subject to rapamycin inhibition, one can not immediately attribute any and all effects of rapamycin to S6K1. We overexpressed S6K1 to determine whether the effects of rapamycin on VSMC differentiation are mediated by this kinase. While wild type S6K1 retains rapamycin-sensitivity, high level overexpression confers a degree of rapamycinresistant activity (Fig. 6A) , perhaps by exceeding limiting quantities of an mTOR-regulated inhibitor (29) . The persistence of S6K1 activity in the presence of rapamycin, when other mTOR target proteins are inhibited, or overexpression of a rapamycin-resistant S6K1 mutant, allows us to assign a role specifically to S6K1. In these studies, overexpression of S6K1 was mutually exclusive with rapamycin-induced contractile protein and p21 cip expression. These data suggest that mTOR normally opposes VSMC differentiation through activation of S6K1, and that rapamycin inhibition of this kinase promotes differentiation.
The effect of S6K1 overexpression on basal levels of differentiation markers varied somewhat in that basal expression of SM2-MHC and calponin, but not SM alpha actin and p21 cip , was inhibited by S6K1. We attribute this variation to two factors. It is likely that the enhanced kinase activity of the ED 3 E mutant as opposed to wild type S6K1 contributed to inhibition of basal SM2-MHC expression (Fig. 6E, left panel) . It is also likely that the effect correlates with the temporal expression of contractile proteins during the differentiation process. SM actin is the earliest marker of the VSMC lineage and its expression is reduced, but not completely inhibited, even in the synthetic phenotype ( Fig. 4D and 6C ). Thus, it is perhaps not surprising that (wild type) S6K1 failed to inhibit basal expression of this protein, but did inhibit that of calponin, an intermediate stage marker, and of SM2-MHC, the most stringent late-stage differentiation marker.
Other than the ribosomal S6 protein, few substrates for S6K1 have been identified.
Notably, the testis-specific transcription factor CREM has been identified as an S6K1 substrate with rapamycin-sensitive transactivation function in vivo (4) . An attractive hypothesis that we aim to pursue is that S6K1 may oppose VSMC differentiation by negatively regulating cell type- S6 kinases are found in several cellular locations. p70 S6K1 is found in both the nucleus and the cytoplasm, while the p85 S6K1 isoform is nuclear (17) . Both isoforms of the related kinase S6K2 are nuclear (18), (9). The roles of the nuclear S6 kinases are largely unknown, but we speculate that S6Ks could potentially regulate differentiation through as yet undetermined nuclear targets.
Our data demonstrate that S6K1 opposes VSMC differentiation, and previous studies have reported rapid activation of S6K1 following vascular injury (1). However, it is likely that inhibition of S6K1 alone is not sufficient for VSMC differentiation: we found that PI3K inhibition with LY294002, which, in turn, leads to S6K1 inhibition (21), did not promote VSMC differentiation (Fig. 4C) . We postulate that while S6K1 may oppose differentiation, promotion Using inhibitors of multiple signaling pathways, we found that only inhibition of the mTOR pathway induced VSMC differentiation. Previous studies suggest that the ERK MAPK pathway is pro-proliferative in vascular smooth muscle cells (11) . While inhibition of this pathway could conceivably contribute to differentiation, we did not observe such an effect. It may be that ERK signals are required for proper function of the CArG DNA regulatory elements common to most muscle-specific promoters, including those of the VSMC contractile protein genes (42), (20), (34) .
In response to vessel injury, VSMC de-differentiate to a "synthetic" phenotype, which is named for the copious extracellular matrix synthesis and secretion characteristic of these cells.
Because the major known function of the mTOR pathway is regulation of protein synthesis, rapamycin might be expected to inhibit the synthetic phenotype primarily at the level of inhibition of translation initiation. We found that rapamycin indeed inhibited total protein synthesis, including the major secreted extracellular matrix component collagen. However, Table 1 Statistical analysis of contractile protein induction by rapamycin 
